Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M
Immusoft, a Seattle-based biotech has announced a partnership with Takeda to create treatments for rare neurometabolic conditions.
As a result of the $900 million deal, Takeda can license programs during the preclinical stage as well as take products to the clinic and through the commercialization process.
“This advances our leadership position in B cells as biofactories for therapeutic protein delivery,” said Sean Ainsworth, CEO of Immusoft.